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Introduction 
Image-guided intensity-modulated radiotherapy (IG-IMRT) has 
been widely used in the treatment of prostate cancer, with the 
goal of reducing acute and late toxicity of adjunct critical organs, 
e.g., the bladder and rectum [1,2]. Helical tomotherapy is consid-
ered a favorable treatment technique for prostate cancer due to 
its uniformity in treatment and the fact that it is based on com-
puted tomography (CT) simulation [3,4]. 
Magnetic resonance imaging (MRI) has been shown to be supe-
Purpose: To evaluate and compare the feasibilities of magnetic resonance (MR) image-based plan-
ning using synthetic computed tomography (sCT) versus CT (pCT)-based planning in helical tomother-
apy for prostate cancer. 
Materials and Methods: A retrospective evaluation was performed in 16 patients with prostate can-
cer who had been treated with helical tomotherapy. MR images were acquired using a dedicated 
therapy sequence; sCT images were generated using magnetic resonance for calculating attenuation 
(MRCAT). The three-dimensional dose distribution according to sCT was recalculated using a previ-
ously optimized plan and was compared with the doses calculated using pCT. 
Results: The mean planning target volume doses calculated by sCT and pCT differed by 0.65% ± 
1.11% (p = 0.03). Three-dimensional gamma analysis at a 2%/2 mm dose difference/distance to 
agreement yielded a pass rate of 0.976 (range, 0.658 to 0.986). 
Conclusion: The dose distribution results obtained using tomotherapy from MR-only simulations 
were in good agreement with the dose distribution results from simulation CT, with mean dose differ-
ences of less than 1% for target volume and normal organs in patients with prostate cancer. 
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rior to CT with respect to the characterization and visualization of 
soft tissue. Compared to CT with target delineation, CT-MR fusion 
images enable more precise identification of the target volume in 
the prostate, seminal vesicles, and pelvic lymphatics [5-8] and thus 
have the potential to reduce complications of critical organs [9,10]. 
However, the uncertainty of CT-MR registration can propagate 
to target delineation [11]. To eliminate this uncertainty, MR-only 
simulations in radiotherapy (RT) can be used [12]. Various tech-
niques for creating synthetic CT (sCT) images have been proposed 
and validated, e.g., assigning fixed densities to tissues [13], using 
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atlas-based segmentation from databases [14,15], and correlating 
Hounsfield units (HUs) and MR intensities [16,17]. 
The aim of this study was to evaluate a technique for generat-
ing sCT images using a dedicated MRI pulse sequence and an al-
gorithm in a dedicated MR-RT simulator. Additionally, we aimed 
to calculate the residual treatment dose discrepancy between 
planning CT (pCT) and sCT using a helical tomotherapy plan for 
prostate cancer as a reference. Finally, we set out to assess the 
feasibility of MR-only simulations with helical tomotherapy for 
patients with prostate cancer. 
Materials and Methods 
1. Patient characteristics 
This study included treatment plans for 16 patients with prostate 
cancer who were treated with helical tomotherapy. The patient 
characteristics are summarized in Table 1. The median patient age 
was 73 years (range, 59 to 83 years). Eleven patients were treated 
with definitive (curative intent) RT, while the rest were treated 
with salvage RT. Surgical bed was included in the treatment field 
for 4 patients; elective pelvic lymph node areas were additionally 
treated in 12 patients. This study was approved by the Institution-
al Review Board of Samsung Medical Center, Korea approved this 
retrospective study (No. 2016-07-109-001). The requirement for 
informed consent was waived.
2. pCT imaging 
Each patient was immobilized using a vacuum cushion and posi-
tioned in the head-first supine position with both arms placed on 
the chest. A catheter with a small rectal balloon filled with 60 mL 
of air was inserted into the rectum. Three-dimensional (3D) CT im-
ages (pixel spacing 0.98 mm ×  0.98 mm, 512 ×  512) were ac-
quired using a Discovery CT590RT (GE Healthcare, Waukesha, WI, 
USA). The slice thickness was 2.5 mm. Contrast medium (90 mL) 
was injected at a flow rate of 2 mL/s. 
3. MR imaging and generation of sCT images 
MR scans were conducted immediately after the pCT scans on the 
same day using a 3.0 T Ingenia MR simulation system (Philips 
Healthcare, Best, The Netherlands). These systems are dedicated for 
radiation therapy and are equipped with a 16-channel abdominal 
receiving coil and integrated posterior coil assembly. The patient 
setup was the same as in the pCT simulation, with the exception 
that the feet-first-supine orientation was used. This position al-
lowed more flexibility than the head-first setup when positioning 
the anterior receiving coil. A dedicated 3D radiofrequency spoiled 
incoherent gradient 2-echo instrument (3D-T1-FFE 2-echo; repeti-
tion time [TR], 3.8 ms; echo time-1 [TE1], 1.2 ms; TE2, 2.4 ms; flip 
angle, 10º) was used to collect the source images. Two sets of 
T1-weighted MR images with different TEs were obtained. 
Next, two-point mDixon reconstruction was used to generate 
three sets of MR images: in-phase, water-only, and fat-only (Fig. 1A, 
1B, and 1C, respectively). To generate the sCT images, a dedicated 
post-processing algorithm [18,19] was utilized. The sCT images 
were generated automatically using a magnetic resonance calcu-
lating attenuation (MRCAT) algorithm, as shown in Fig. 1D. The 
MRCAT sCT images consisted of air, fat, normal tissue, spongy 
bone, and compact bone; the materials were assigned -968, -86, 
42, 198, and 949 HUs, respectively. The sCT images were 432 ×  
432 pixels, with pixel spacing of 1.04 mm ×  1.04 mm and a slice 
thickness of 2.5 mm.  
4. Treatment plans for tomotherapy on pCT 
In treatment planning, 3D CT images were used as the reference 
(pCT). The primary clinical target volume (CTV1), which included 
the surgical bed, was delineated on the pCT images using a Pinna-
cle3 system (v.9.10; Philips Medical Systems, Fitchburg, WI, USA). 
Pelvic lymphatics were delineated as the secondary clinical target 
volume (CTV2) in 12 patients. A setup margin (SM) of 3–5 mm was 
added to the CTV1 to create the planning target volume (PTV1), 
Table 1. Patients’ characteristics (n = 16)
Characteristic Value
Age (yr) 73 (59–83)
T stage
 T2 3 (18.75)
 T3a 5 (31.25)
 T3b 7 (43.75)
 T4 1 (6.25)
Initial PSA (ng/mL)
 <10 4 (25.00)
 10–20 4 (25.00)
 >20 8 (60.00)
Grade
 6 2 (12.50)
 7 3 (18.75)
 8–9 11 (68.75)
Treatment aim
 Definitive 11 (68.75)
 Salvage 5 (31.25)
Radiation field
 Surgical bed only 4 (25.00)
 Whole pelvis 12 (75.00)




and an SM of 5–7 mm was added to the CTV2 to create the PTV2. 
IMRT plans were performed using TomoTherapy planning sta-
tions (Hi-Art ver. 4.2.3 or TomoHD ver. 1.2.3; Accuray Inc., Sunny-
vale, CA, USA). The prescribed doses to the PTV1 (1ºDpre) and PTV2 
(2ºDpre) were 70.0 Gy and 50.4 Gy, respectively, at 28 fractions. The 
dose constraints in the treatment plans were: (1) the 1ºDpre had to 
cover at least 98% of the PTV, and (2) the maximum dose (Dmax) of 
the PTV had to be less than 107% of the 1ºDpre. Doses to organs-
at-risk (OARs), such as the rectum wall, bladder, penile bulb, fem-
oral heads, and bowel, were also considered. 
5. Dose calculation on sCT 
The 3D dose distribution based on the sCT results was calculated 
using the optimized reference treatment plan on the pCT images. 
To this end, the delivery quality application (DQA) of a tomotherapy 
workstation was used. The sCT image was registered rigidly to the 
pCT image and resampled to match the dimensions and patient 
positions of the sCT image to those of the pCT image using MIM 
Maestro ver. 6.4.9 (MIM Software, Cleveland, OH, USA). The struc-
tures of the target volumes and normal organs delineated on pCT 
were copied to the structures on sCT. All registrations and struc-
tures on sCT were validated by both a physician and a physicist. 
The couchtop was not visible on the sCT image from the MRI 
scan. Since the sCT image was already registered to the pCT im-
age, a virtual couch was inserted into the sCT image at the same 
position of the pCT image in the DICOM coordination. The sCT im-
ages were modified to be similar to phantom images [20] and 
were then imported into the DQA workstation for recalculation of 
the 3D dose. 
6. Dosimetric analysis 
To evaluate the clinical feasibility of using sCT in a tomothera-
py-based treatment plan, the image values, dosimetric parameters, 
and 3D doses recalculated using the sCT images were compared to 
those calculated using the pCT images. Specifically, the mean HUs 
of the target volumes, OARs, and materials on the pCT and sCT 
images were calculated and compared. Dosimetric parameters 
such as Dmean, D5%, and D95% were calculated from the dose-volume 
histograms (DVHs) and compared in order to evaluate differences 
in the planned doses delivered to the target volumes; Dmean and 
Dmax were compared to evaluate dose differences to OARs. In addi-
tion, the 3D gamma values were evaluated with the global dose 
criteria of 3%/3 mm–1%/1 mm (dose difference/distance to 
agreement). 
Statistical differences in the dosimetric parameters from the 
different dose distributions were assessed using the Wilcoxon 
A B C
D E
Fig. 1. Representative magnetic resonance image used for calculation attenuation (MRCAT). (A) In-phase, (B) water-only, and (C) fat-only MR 
images for patient #13 were generated from the three-dimensional T1-weighted mDixon images using 2 echoes. (D) The synthetic computed 
tomography (CT) image was generated using the MRCAT and MR images. (E) A planning CT image was acquired from the CT simulation.
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signed-rank test. The test was performed using SPSS v. 20.0 (IBM 
Corp., Armonk, NY, USA). A p-value ≤0.05 was considered to be 
statistically significant.  
Results  
1. Differences in HUs 
After automatic generation of the sCT images from the MR images 
using the MRCAT algorithm, treatment plans were determined, 
and dose recalculations were performed using the sCT images. The 
differences in HUs between the sCT images and the pCT images 
are summarized in Table 2. The mean differences of the target vol-
umes and OARs were evaluated to be less than 30, with the ex-
ception of the rectum wall and femoral heads. Since the air in the 
rectal balloon could not be represented on the sCT images by MR-
CAT, the greatest HU differences were observed for the rectum 
wall. The differences in the mean HUs for fat and muscle were 
evaluated to be less than 10. 
2. Dosimetric parameters 
Three-dimensional dose for all the patients were re-calculated and 
DVHs were compared as shown in Fig. 2. Dosimetric parameters of 
the target volumes and OARs from the DVHs were summarized and 
compared in Table 3. The mean differences in Dmean, D95%, and D5% 
for PTV1 and PTV2 between pCT and sCT were all less than 0.74 Gy. 
The Dmean and D5% sCT values were both statistically different from 
the pCT values; however, the absolute differences of the mean val-
ues of all parameters were less than 1.04%. Due to the HU differ-
ences for fat and muscle in the body outlines, the Dmean and Dmax 
values calculated from the sCT images for the rectum wall, right 
femoral head, left femoral head, and penile bulb were also signifi-
cantly different from those calculated from the pCT images; in 
contrast, the bladder values were not significantly different. How-
ever, for all OARs, the normalized Dmean and Dmax values, using 1ºDpre 
(70 Gy), were less than 0.59% and 1.59%, respectively. 
3. Gamma evaluation 
The results of the 3D gamma analysis at 3%/3 mm, 2%/2 mm, and 
1%/1 mm dose difference/distance to agreement are shown in Fig. 
3. With respect to overall volume, gamma analysis revealed pass 
rates of 0.998 (range, 0.981 to 1.000), 0.976 (range, 0.658 to 0.986), 
and 0.871 (range, 0.540 to 0.931), with γ50 values of 0.123 (range, 
0.084 to 0.203), 0.190 (range, 0.128 to 0.460), and 0.379 (range, 
0.257 to 0.920), respectively. For the target volumes and critical or-
gans, the median and mean pass rates at 3%/3 mm and 2%/2 mm 
were both greater than 0.95, with γ50 values less than 0.5. 
Discussion and Conclusion 
We demonstrated the feasibility of MR-only simulations using he-
lical tomotherapy for patients with prostate cancer. Tomotherapy 
and the associated planning algorithms comprise one of the most 
advanced radiation therapy techniques, while MR is the preferred 
medical imaging method for patients with prostate cancer. We 
successfully treated 16 patients with prostate cancer with con-
ventional CT using tomotherapy and acquired MR images in the 
Table 2. Comparison of mean image values (unit: HU)
Planning CT Synthetic CT Difference p-value
Target volumes
 PTV1 (n =  16) 14.0 ±  24.9 23.4 ±  13.1 9.5 ±  26.1 0.07
 PTV2 (n =  12) 33.4 ±  14.2 -6.8 ±  8.0 -30.2 ±  20.3 <0.01*
Normal organs (n =  16)
 Bladder 18.6 ±  7.1 35.3 ±  6.1 16.7 ±  10.5 <0.01*
 Rectum wall -143.3 ±  156.6 4.6 ±  10.3 147.9 ±  154.4 <0.01*
Femoral head
 Right 279.5 ±  45.8 175.5 ±  6.1 -104.0 ±  47.5 <0.01*
 Left 280.4 ±  50.5 177.7 ±  6.4 -102.7 ±  51.7 <0.01*
 Penile bulb 48.3 ±  14.7 40.3 ±  2.5 -8.0 ±  14.0 0.02*
Fat and muscle volumes (n =  16)
 Fat -69.4 ±  13.6 -77.3 ±  1.4 -7.9 ±  13.0 0.02*
 Muscle 34.1 ±  12.4 39.8 ±  0.4 5.7 ±  12.3 0.05*
Values are presented as mean ± standard deviation.
CT, computed tomography; HU, Hounsfield unit; PTV, planning target volume.
*p < 0.05, Wilcoxon paired signed-rank test.
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Table 3. Comparison of dosimetric parameters for target volumes, normal organs, and fat/muscle volumes
Parameter Planning CT (Gy) Synthetic CT (Gy) Difference (Gy) Normalizeddifference (%) p-values
Target volumes PTV1 (n =  16) Dmean 70.00 ±  0.61 70.46 ±  1.07 0.46 ±  0.77 0.65 ±  1.11 0.03*
D95% 67.86 ±  2.19 68.20 ±  2.17 0.33 ±  0.84 0.48 ±  1.19 0.16
D5% 71.47 ±  0.79 72.20 ±  1.16 0.73 ±  0.74 1.04 ±  1.05 <0.01*
PTV2 (n =  12) Dmean 50.92 ±  1.01 51.24 ±  1.21 0.32 ±  0.50 0.34 ±  0.65 0.06
D95% 47.17 ±  2.44 47.33 ±  2.45 0.12 ±  0.48 0.17 ±  0.68 0.34
D5% 57.28 ±  5.14 57.75 ±  5.24 0.35 ±  0.47 0.50 ±  0.67 <0.01*
Normal organs (n =  16) Bladder Dmean 40.19 ±  7.19 40.28 ±  7.39 0.09 ±  0.52 0.12 ±  0.75 0.98
Dmax 70.45 ±  1.00 70.55 ±  1.34 0.10 ±  0.80 0.14 ±  1.14 0.97
Rectum wall Dmean 30.72 ±  3.06 30.44 ±  2.89 -0.28 ±  0.44 -0.41 ±  0.63 0.03*
Dmax 70.02 ±  1.10 71.13 ±  1.65 1.11 ±  0.86 1.59 ±  1.23 <0.01*
Right femoral head Dmean 21.35 ±  4.55 21.68 ±  4.64 0.33 ±  0.24 0.48 ±  0.34 <0.01*
Dmax 34.92 ±  7.72 35.57 ±  7.98 0.65 ±  0.43 0.93 ±  0.61 <0.01*
Left femoral head Dmean 20.93 ±  4.10 21.26 ±  4.19 0.33 ±  0.23 0.47 ±  0.33 <0.01*
Dmax 34.53 ±  7.18 35.21 ±  7.48 0.67 ±  0.47 0.96 ±  0.67 <0.01*
Penile bulb Dmean 39.05 ±  14.86 39.46 ±  14.98 0.41 ±  0.41 0.59 ±  0.59 <0.01*
Dmax 52.42 ±  14.84 52.97 ±  15.15 0.55 ±  0.69 0.79 ±  0.98 <0.01*
Fat and muscle volumes (n = 16) Fat Dmean 11.16 ±  4.00 11.28 ±  4.04 0.12 ±  0.08 0.17 ±  0.11 <0.01*
Dmax 46.65 ±  9.14 47.02 ±  9.26 0.37 ±  0.51 0.53 ±  0.73 0.01*
Muscle Dmean 12.66 ±  4.15 12.81 ±  4.19 0.16 ±  0.09 0.22 ±  0.13 <0.01*
Dmax 54.16 ±  7.51 54.78 ±  7.79 0.62 ±  0.69 0.88 ±  0.99 <0.01*
Values are presented as mean ± standard deviation.
CT, computed tomography; PTV, planning target volume; D95%, dose covering 95% of target volume; Dmean, mean dose; D5%, dose covering 5% of tar-
get volume; Dmax, dose delivered to 2% of organ volume.
*p < 0.05, Wilcoxon paired signed-rank test.
Fig. 2. Representative dosimetric results. (A, B) display the three-dimensional dose distributions as calculated by planning computed tomogra-
phy (CT) and synthetic CT images, respectively, for patient #13. (C, D, E) present comparisons of the three-dimensional doses for patient #13 
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same position on the same day to generate synthetic sCT images. 
The 3D doses calculated based on the sCT images showed good 
agreement with those calculated from the pCT images, as assessed 
by image registration, dosimetric parameters, and gamma analysis. 
Because of superiority MR for delineation of prostate and nor-
mal organs [9], various methodologies generating sCT from MR for 
implement MR only simulation, such as bulky anatomical density 
[21-24], machine learning [25,26] and so on, have been suggested. 
Usually, process of generating sCT from MRI required a specialist 
or specific procedure, however, a commercial MRCAT software, 
used in this study, could generate sCT using the dedicated MR 
protocol automatically. Especially, Tyagi et al. [23,24] evaluated 
dosimetric characteristics and implementation of MR only simula-
tion into a clinical work flow, including feasibility of 2D orthogo-
nal digitally reconstructed radiography generated from sCT or 3D 
sCT for IG-IMRT with standard LINACs (linear accelerators) 
equipped with kV imager. A clinical workflow of tomotherapy is 
constructed with a dedicated  treatment planning system, dose 
calculation, delivery quality assurance, and IGRT with MV cone-
beam CT. We focused on feasibility of MR based tomotherapy for 
prostate. 
During tomotherapy planning, it is necessary to identify the lo-
cation of the CT couchtop and to replace this location with the 
couch model of the tomotherapy machine. Since the couchtop is 
not readily visible on MR images, we attempted to locate the vir-
tual couches on the MR images using couch markers. Since the 
presence of the couch can affect dose calculation in IMRT [27], it 
would be beneficial for the sCT algorithm to automatically identify 
the couchtop location for other rotating treatments, such as volu-
metric modulated arc therapy. 
The DQA station was the only method by which the dose could 
be recalculated from the sCT images using the previously opti-
mized plan without any additional modifications. Since the DQA 
workstation does not permit any modifications to the treatment 
plan, the density of the rectal balloon outline could not be modi-
fied and overridden in dose recalculation using this workstation. A 
rectal balloon was used in both the CT and MR scans; the balloon 
showed a mean HU of -143.3 on the pCT images. However, since 
air in the body outline was not allowed in the MRCAT algorithm 
and the air of the rectal balloon was assigned a mixture of the HU 
values of fat and water, the mean HU of the rectal area on the sCT 
images was calculated to be 4.6. 
Due to the apparent lack of air in the rectal balloon on the sCT 
images, somewhat higher doses to target volumes were calculated 
from the sCT images. Thus, the gamma passing rates using the 
1%/1 mm criteria for the PTV1, PTV2, bladder, and rectum were 
lower than those for other organs (Fig. 3A). However, the overall 
gamma analysis results with the 3%/3 mm and 2%/2 mm criteria 
showed excellent agreement between the pCT and sCT dose calcu-
lations. If the clinical protocol for prostate tomotherapy is estab-
lished without using the air-filled rectal balloon or if the density 
of the rectal balloon outline could be modified, this significant 
difference in target dose would decrease significantly. 
In addition, the mean differences in the HUs of bone (both fem-
oral heads), fat, and muscle were calculated to be -103.4, -7.9, 




















































































Fig. 3. Gamma analysis results at 3%/3 mm, 2%/2 mm, and 1%/1 mm dose difference/distance to agreement. (A) Pass rates for the target vol-
umes and organs-at-risk and (B) median gamma analysis (γ50) values. PTV, planning target volume; LT, left; RT, right.
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umes and OARs calculated using the sCT images were statistically 
different from those calculated using the pCT images, the mean 
differences were all less than 17 HU, with the exception of both 
femoral heads and the rectal wall. Although these HU differences 
did not significantly affect the final dose distribution, we intend 
to improve and reduce these differences in future algorithms. The 
MRCAT algorithm we used here utilizes five materials (air, fat, nor-
mal tissue, spongy bone, and compact bone); we plan to validate 
other algorithms in future analyses. 
We observed small spatial discrepancies in the external body 
outlines on the sCT and pCT images (Fig. 2C). These discrepancies 
were due to the use of the anterior coil in the MR scan, which was 
placed directly on top of the patient. In addition, although we ac-
quired the MR images right after the CT simulation with the pa-
tient in the same position, setup uncertainties resulted from the 
time difference between the CT and the MR acquisitions. However, 
these uncertainties can be minimized by performing overall dose 
calculations considering the daily setup variations with fractionat-
ed treatments and by using dedicated positioning devices for 
MR-only simulations [28]. 
All 16 of our prostate cancer CT simulations and MR simulations 
were performed on the same day. Although we endeavored to ac-
quire the MR images immediately after the CT simulations, it was 
sometimes difficult to suitably arrange the logistics of this se-
quence in busy clinics; moreover, some patients had to wait for 
their bladders to fill. Despite these limitations, we demonstrated 
the feasibility of combining tomotherapy with MR-only simula-
tions. We intend to expand this strategy to other radiation therapy 
techniques using X-ray machines and to other particle therapy 
machines such as proton and carbon machines. 
Inter-target and intra-target delineation variations for prostate 
cancer with CT-only images can yield variable IMRT planning re-
sults. Although rigid or deformable registration using CT and MR 
provides an avenue by which target structures can be delineated, 
CT-MR fusion has several limitations such as variable examination 
time, different immobilization devices, and variations in position. 
MR-only simulations promise more detailed anatomical informa-
tion than CT and have the potential to reduce other uncertainties 
due to their improved soft tissue contrast, single immobilization 
device setting, and precise treatment positions. 
Based on the results of this feasibility study, we anticipate that 
MR-only simulations will play an important role in IMRT and other 
advanced treatment techniques for patients with prostate cancer 
and other types of cancer. Dedicated MR sequences and the MR-
CAT sCT algorithm were retrospectively applied to determine the 
radiation therapy workflows. The entire process, including sCT im-
age generation and radiation therapy planning based on sCT, was 
validated as a feasible approach combining tomotherapy and MR 
simulation. Tomotherapy planning using MR-only simulation has 
good accuracy and is clinically feasible with mean dose differenc-
es of less than 1% for the target volumes and normal organs. We 
intend to implement MR-only simulation tomotherapy in our clin-
ic for treating prostate cancer in order to reduce the time pressure 
for CT simulation and for other planning and treatment processes. 
Further studies will focus on improving the MRI scanning proto-
cols, investigating other issues raised in this study, and applying 
this method to other diseases and treatment machines. 
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